Financial Architects (New Jersey)’s Sarepta Therapeutics SRPT Stock Holding History

Financial Architects (New Jersey)’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$24K	–	1444
2019 Q1	$24K	Buy	+200	New	+$25.7K	﹤0.01%	832
2018 Q4	–	Sell	-200	Closed	-$32K	–	1490
2018 Q3	$32K	Buy	+200	New	+$27.3K	0.01%	787
2016 Q4	–	Sell	-2,000	Closed	-$83K	–	1490
2016 Q3	$83K	Buy	2,000 +300	+18%	+$9.07K	0.02%	432
2016 Q2	$6K	Buy	+1,700	New	+$31.5K	﹤0.01%	1090

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Architects (New Jersey)'s SRPT Position: Q2 2019 in Review

Financial Architects (New Jersey) sold out of Sarepta Therapeutics (SRPT) in Q2 2019, closing a stake of 5 shares — an estimated $1K sold.

Financial Architects (New Jersey) first reported a position in SRPT in Q2 2016 and held it in 12 quarters. The position peaked at $15K in Q1 2018. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

Financial Architects (New Jersey) reported no remaining Sarepta Therapeutics position as of Q2 2019 after selling out during the quarter.
Financial Architects (New Jersey) sold 5 Sarepta Therapeutics shares in Q2 2019, an estimated $1K.
Financial Architects (New Jersey) first reported a position in Sarepta Therapeutics in Q2 2016 and held it in 12 quarters.
Financial Architects (New Jersey)'s Sarepta Therapeutics position peaked at $15K in Q1 2018.
365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2019, filed 14 Aug 2019.